Overview

ZW25 in Women With Endometrial Cancers

Status:
Recruiting

Trial end date:
2022-04-12

Target enrollment:

Participant gender:

Summary

This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Zymeworks Inc.